Foundation Fighting Blindness
Foundation Fighting Blindness
Add to My Podcasts
Episodes
About
Reviews
Promote
J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
2 minutes
Posted May 15, 2025 at 2:07 pm.
0:00
2:35
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Despite missing the primary endpoint, the treatment improved vision for some patients.
Previous
ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)
Next
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
← See all 261 episodes of Foundation Fighting Blindness